https://stage--stage-takhzyro--onetakeda.aem.page/hcp/safety-profile/fragments/safety-header
Style
section-no-margin, section-no-padding

HELP STUDY

HELP OLE STUDY

REAL WORLD EMPOWER STUDY

SPRING STUDY

Style
Inner-content-contained, section-no-top-margin, section-no-bottom-margin, flex-stretch, section-no-top-padding, section-no-bottom-padding, pink-tertiary-btn

Safety profile seen in patients as young as 2 years of age1

Safety data of 21 pediatric patients taking TAKHZYRO for 52 weeks1

Most common related TEAEs3*
TAKHZYRO 150 mg every 2 or 4 weeks
(N=21)
Injection site pain
29%
Injection site erythema
14%
Injection site swelling
5%
Administration site pain
5%
Injection site reaction
5%

The profile of related TEAEs was similar between the every-2-weeks and every-4-weeks dosing treatment groups.3

No deaths, serious TEAEs, hospitalizations, or discontinuations due to TEAEs were observed.3

No new safety signals were observed in these patients. Overall, the safety was similar between adult patients and pediatric patients (2 to <18 years of age).1

*Treatment-related TEAEs were TEAEs classified as related to lanadelumab treatment by the investigator.3
TEAE=treatment-emergent adverse event.

Style
Inner-content-contained, section-no-top-margin, section-no-bottom-margin, section-no-bottom-padding, section-footnote, h4-green, section-safety-tabs, body-font-14, first-p-margin

Explore more safety information

HELP STUDY

HELP OLE STUDY

REAL WORLD EMPOWER STUDY

Style
Inner-content-contained, section-no-bottom-margin, flex-stretch, section-no-bottom-padding, section-no-top-padding
https://stage--stage-takhzyro--onetakeda.aem.page/hcp/safety-profile/fragments/offers-info
Style
section-no-top-padding, section-no-bottom-margin, section-no-bottom-padding, background-lavender-light, inner-content-contained

References: 1. Takhzyro. Prescribing information. Dyax Corp; 2025. 2. Banerji A, Riedl MA, Bernstein JA, et al. JAMA. 2018;320(20):2108-2121. doi:10.1001/jama.2018.16773 3. Maurer M, Lumry WR, Li HH, et al; SPRING Investigators. J Allergy Clin Immunol Pract. Published online September 18, 2023. doi:10.1016/j.jaip.2023.09.009

Style
Inner-content-contained, section-references, section-no-top-margin, section-no-bottom-margin
https://main--takeda-eds-sites-takhzyro--onetakeda.hlx.page/hcp/fragments/isi
Style
Inner-content-contained, section-no-margin
id
important-safety-information